AstraZeneca: Covid-19 vaccine begins final-stage testing
(CercleFinance.com) - AstraZeneca said on Monday that an experimental coronavirus vaccine entered the late stage phase of its studies, with the first subjects set to receive doses of this vaccine that was jointly invented by the University of Oxford.
Researchers assessing the safety, efficacy, and immunogenicity of AZD1222 compared to placebo in this Phase III clinical trial plan to enroll up to 30,000 adults aged 18 years or over, the company said.
Participants will come from diverse racial, ethnic and geographic groups who are healthy or have stable underlying medical conditions, including people living with HIV, and who are at increased risk of infection from the virus, AstraZeneca said.
Patients are being randomly selected to receive two doses of either AZD1222 or a saline control, four weeks apart, with twice as many participants receiving the potential vaccine than the saline control.
Systemic reactions and immune responses will be assessed in 3,000 participants, with results due later this year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.
Researchers assessing the safety, efficacy, and immunogenicity of AZD1222 compared to placebo in this Phase III clinical trial plan to enroll up to 30,000 adults aged 18 years or over, the company said.
Participants will come from diverse racial, ethnic and geographic groups who are healthy or have stable underlying medical conditions, including people living with HIV, and who are at increased risk of infection from the virus, AstraZeneca said.
Patients are being randomly selected to receive two doses of either AZD1222 or a saline control, four weeks apart, with twice as many participants receiving the potential vaccine than the saline control.
Systemic reactions and immune responses will be assessed in 3,000 participants, with results due later this year.
Copyright (c) 2020 CercleFinance.com. All rights reserved.